EUVIMEDEUVIMED entdecken
Crossref

Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease

Thomas A Mavrakanas, Nadia Giannetti, Ruth Sapir-Pichhadze, Ahsan Alam

Cardiorenal Medicine · 2020 · 10 (1) · 32-41

DOI: 10.1159/000503223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiorenal Medicine, online erschienen am 30.10.2019. Verfasst von Thomas A Mavrakanas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada, thomas.mavrakanas@mail.mcgill.ca. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The effect of mineralocorticoid receptor antagonists (MRAs) on chronic kidney disease (CKD) progression in patients with heart failure (HF) and with or without preexisting CKD has not been adequately studied.

Methods

We conducted a retrospective cohort study including consecutive adult patients followed at the HF clinic of a tertiary care center who had already been on an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB). Exposure to MRAs was assessed at 6 months from registration. Patients who were never exposed to an MRA were the control group.

Results

A total of 314 patients who were prescribed an MRA were compared to 1,116 patients who never received an MRA. Among them, 121 and 408 patients, respectively, had CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2). MRAs had to be discontinued in 36/121 patients with CKD (29.8%) and 57/165 patients without CKD (34.5%) (p = 0.39). MRA treatment was associated with a higher risk for persistent creatinine doubling among patients without CKD (hazard ratio 4.07, 95% confidence interval 1.41–11.73). A numerically lower risk was identified among CKD patients (hazard ratio 0.33, 95% confidence interval 0.04–2.78) (p for interaction = 0.009). The primary safety outcome, a composite of any doubling of serum creatinine or any episode of serious hyperkalemia (K+ >6 mmol/L), occurred more commonly in MRA users compared with nonusers in the subgroup of patients without CKD, but not in CKD patients (p for interaction = 0.02).

Conclusion

MRA treatment in addition to an ACEI or an ARB could be safely prescribed in HF patients with CKD as it is not associated with persistent renal function decline, acute kidney injury, or serious hyperkalemia, compared with ACEI/ARB monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryAdultAgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCase-Control StudiesCreatinineDisease ProgressionDrug Therapy, CombinationFemaleGlomerular Filtration RateHeart FailureHumansHyperkalemiaMaleMiddle AgedMineralocorticoid Receptor AntagonistsOutcome Assessment, Health CareRenal Insufficiency, ChronicRetrospective Studies

Stichwörter der Autor:innen

Chronic kidney diseaseHeart failureHyperkalemiaMineralocorticoid receptor antagonistsProgression of chronic kidney disease

Substanzen

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsMineralocorticoid Receptor AntagonistsCreatinine

Autor:innen und Institutionen

  • Divisions of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada, thomas.mavrakanas@mail.mcgill.ca.
  • Department of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, thomas.mavrakanas@mail.mcgill.ca.
  • Division of Cardiology, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada.
  • Divisions of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada.

Zitieren

APA

Mavrakanas, T. A., Giannetti, N., Sapir-Pichhadze, R., & Alam, A. (2020). Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease. Cardiorenal Medicine, 10(1), 32-41. https://doi.org/10.1159/000503223

Vancouver

Mavrakanas TA, Giannetti N, Sapir-Pichhadze R, Alam A. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease. Cardiorenal Medicine. 2020;10(1):32-41. doi:10.1159/000503223

BibTeX
@article{Mavrakanas2020,
  author = {Mavrakanas, Thomas A and Giannetti, Nadia and Sapir-Pichhadze, Ruth and Alam, Ahsan},
  title = {Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease},
  journal = {Cardiorenal Medicine},
  year = {2020},
  volume = {10},
  number = {1},
  pages = {32--41},
  doi = {10.1159/000503223}
}
Kostenlos starten →